AU2020407239B2 - Methods of treating brain disorders - Google Patents

Methods of treating brain disorders

Info

Publication number
AU2020407239B2
AU2020407239B2 AU2020407239A AU2020407239A AU2020407239B2 AU 2020407239 B2 AU2020407239 B2 AU 2020407239B2 AU 2020407239 A AU2020407239 A AU 2020407239A AU 2020407239 A AU2020407239 A AU 2020407239A AU 2020407239 B2 AU2020407239 B2 AU 2020407239B2
Authority
AU
Australia
Prior art keywords
nac
brain
congener
subject
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020407239A
Other languages
English (en)
Other versions
AU2020407239A1 (en
Inventor
Thomas I. Bradshaw
Douglas A. GREENE
Rajiv R. Ratan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Burke Neurological Institute
Neuronasal Inc
Original Assignee
Burke Neurological Inst
Burke Neurological Institute
Neuronasal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burke Neurological Inst, Burke Neurological Institute, Neuronasal Inc filed Critical Burke Neurological Inst
Publication of AU2020407239A1 publication Critical patent/AU2020407239A1/en
Application granted granted Critical
Publication of AU2020407239B2 publication Critical patent/AU2020407239B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020407239A 2019-12-18 2020-12-18 Methods of treating brain disorders Active AU2020407239B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949640P 2019-12-18 2019-12-18
US62/949,640 2019-12-18
US202062970254P 2020-02-05 2020-02-05
US62/970,254 2020-02-05
PCT/US2020/066179 WO2021127541A1 (en) 2019-12-18 2020-12-18 Methods of treating brain disorders

Publications (2)

Publication Number Publication Date
AU2020407239A1 AU2020407239A1 (en) 2022-07-28
AU2020407239B2 true AU2020407239B2 (en) 2025-11-27

Family

ID=76437600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020407239A Active AU2020407239B2 (en) 2019-12-18 2020-12-18 Methods of treating brain disorders

Country Status (7)

Country Link
US (3) US12090130B2 (https=)
EP (1) EP4076425A1 (https=)
JP (1) JP2023518635A (https=)
CN (1) CN115484945A (https=)
AU (1) AU2020407239B2 (https=)
CA (1) CA3165422A1 (https=)
WO (1) WO2021127541A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380291A1 (en) * 2019-11-04 2022-05-26 Neuronasal, Inc. Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2022067232A1 (en) * 2020-09-28 2022-03-31 Commercial Automation, Llc Food product storage and vending kiosk
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP2749552B1 (en) 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
CA2871774C (en) 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
BR112017025499A2 (pt) 2015-05-28 2018-08-07 Baylor College Medicine benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Also Published As

Publication number Publication date
US12414929B2 (en) 2025-09-16
CA3165422A1 (en) 2021-06-24
US20240390313A1 (en) 2024-11-28
EP4076425A1 (en) 2022-10-26
US12090130B2 (en) 2024-09-17
WO2021127541A1 (en) 2021-06-24
CN115484945A (zh) 2022-12-16
US20210186911A1 (en) 2021-06-24
JP2023518635A (ja) 2023-05-08
AU2020407239A1 (en) 2022-07-28
US20260007626A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
US12414929B2 (en) Methods of treating brain disorders
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20120232017A1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20190314297A1 (en) Combination therapy of cbd and copaxone
Tanne et al. Severe tramadol overdoses in children: a case series admitted to paediatric intensive care unit
US20240024267A1 (en) Methods of administering glutathione precursors
Herold Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder
CN114828960A (zh) 治疗儿童个体的cln2病的方法
US12594254B2 (en) Intranasal administration of n-acetylcysteine and uses thereof
HK40077860A (en) Methods for treating cln2 disease in pediatric subjects
Ivaturi Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration
AU2021476139A1 (en) Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
Henderson et al. Coma, Head Trauma, and Spinal Cord Injury
Mistry et al. Neuromuscular Respiratory Failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)